| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Myriad Genetics, Inc. (MYGN) has 9 insiders with recent SEC Form 4 filings, including 0 buys and 14 sells. MYGN is classified in the Life Sciences Tools & Services industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 1.07M | $4.81M | - | |
| Other | 573.4K | $2.58M | - | |
| COO | 381.8K | $1.72M | - | |
| Other | 251.9K | $1.13M | - | |
| Other | 170.2K | $765.8K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 6, 2022 | Spiegelman Daniel K59 | Director | Sell | 6,424 | $19.25 | $123,672.92 | -15.9% | +14.0% | +20.5% | |
| Feb 28, 2022 | Hart Jayne B.64 | Chief People Officer | Sale+OE | 10,500 | $25.00 | $262,500.00 | -3.1% | -21.1% | -22.4% | |
| Oct 1, 2021 | Lambert Nicole71 | See Remarks | Sell | 1,420 | $31.57 | $44,834.51 | -0.8% | -13.3% | -40.2% | |
| Sep 27, 2021 | Lambert Nicole71 | See Remarks | Sell | 10,112 | $33.10 | $334,746.64 | -5.4% | -16.0% | -44.0% | |
| Sep 23, 2021 | Lanchbury Jerry S81 | Chief Scientific Officer | Sell | 200 | $35.06 | $7,012.00 | - | -22.2% | -46.2% | |
| Sep 17, 2021 | Hart Jayne B.64 | Chief People Officer | Sale+OE | 67,446 | $33.72 | $2,274,279.12 | -27.4% | -28.4% | -36.6% | |
| Aug 27, 2021 | Lambert Nicole71 | See Remarks | Sell | 945 | $34.50 | $32,602.50 | -0.7% | -24.6% | -33.4% | |
| Aug 24, 2021 | Lanchbury Jerry S81 | Chief Scientific Officer | Sale+OE | 80,000 | $35.32 | $2,825,600.00 | -10.3% | -21.6% | -32.1% | |
| Aug 5, 2021 | Phanstiel S. Louise62 | Director | Sale+OE | 47,881 | $35.04 | $1,677,740.66 | -43.7% | -17.5% | -22.6% | |
| Aug 5, 2021 | Lanchbury Jerry S81 | Chief Scientific Officer | Sale+OE | 28,225 | $35.57 | $1,004,008.41 | -10.8% | -17.5% | -22.6% |